Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

One-year data of bimekizumab versus ustekinumab for plaque psoriasis in the BE VIVID trial

3 Jul 2020Dermatology

Kirsty LEE

Share

This content is sponsored. It is intended for healthcare professionals only.

// AUTOIMMUNE DISORDERS Medical writer: | Last updated: | In: Article Keywords Psoriasis is a chronic inflammatory skin disease that affects 1-3% of adults in western countries.  Development of biologic treatments over the past two decades has changed the treatment landscape for inflammatory di

One-year-data-of-bimekizumab-versus-ustekinumab-for-plaque-psoriasis-in-the-BE-VIVID-trial

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026